FDA's plan to phase out animal testing may hurt Charles River's revenues. The DCF model suggests that CRL presents an ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

Ho’ola will pay Oncternal a $3.0 million upfront payment, with $2.25 million paid immediately and $750,000 upon resolution of certain outstanding contractual obligations with third parties. Oncternal ...

Alliance/Market LaunchBio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa 01.07.2025 / 13:15 CET/CESTThe issuer is solely responsible for ...

Antibody therapies constitute a vast global market: currently valued at over $250 billion, the market for antibodies is ...

Worldwide, at least seven people have been "cured" of HIV—or at least have had long-term sustained remission. This means that ...

Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells.

The field of cellular immunotherapy has undergone a profound transformation in recent years, with autologous chimeric antigen receptor (CAR) T-cell therapies emerging as the standard-of-care option ...